Molnupiravir
![]() |
2物価
選択条件:
ブランド
- Sigma-Aldrich Japan
パッケージ
- 5MG
- 25MG
- 生産者Sigma-Aldrich Japan
- 製品番号SML2873
- 製品説明 ≥98% (HPLC)
- 英語製品説明EIDD-2801 ≥98% (HPLC)
- 包装単位5MG
- 価格¥14500
- 更新しました2024-03-01
- 購入
- 生産者Sigma-Aldrich Japan
- 製品番号SML2873
- 製品説明 ≥98% (HPLC)
- 英語製品説明EIDD-2801 ≥98% (HPLC)
- 包装単位25MG
- 価格¥58400
- 更新しました2024-03-01
- 購入
生産者 | 製品番号 | 製品説明 | 包装単位 | 価格 | 更新時間 | 購入 |
---|---|---|---|---|---|---|
Sigma-Aldrich Japan | SML2873 | ≥98% (HPLC) EIDD-2801 ≥98% (HPLC) |
5MG | ¥14500 | 2024-03-01 | 購入 |
Sigma-Aldrich Japan | SML2873 | ≥98% (HPLC) EIDD-2801 ≥98% (HPLC) |
25MG | ¥58400 | 2024-03-01 | 購入 |
プロパティ
融点 :156 - 159°C
貯蔵温度 :-20°C, Inert atmosphere
溶解性 :DMSO (Slightly), Methanol (Slightly)
外見 :Solid
色 :White to Off-White
InChI :InChI=1/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/s3
InChIKey :HTNPEHXGEKVIHG-JFPRWSRANA-N
SMILES :O[C@@H]1[C@@H]([C@@H](COC(=O)C(C)C)O[C@H]1N1C=C/C(=N/O)/NC1=O)O |&1:1,2,3,12,r|
貯蔵温度 :-20°C, Inert atmosphere
溶解性 :DMSO (Slightly), Methanol (Slightly)
外見 :Solid
色 :White to Off-White
InChI :InChI=1/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/s3
InChIKey :HTNPEHXGEKVIHG-JFPRWSRANA-N
SMILES :O[C@@H]1[C@@H]([C@@H](COC(=O)C(C)C)O[C@H]1N1C=C/C(=N/O)/NC1=O)O |&1:1,2,3,12,r|
安全情報
絵表示(GHS): |
![]() |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
注意喚起語: | Danger | ||||||||||||||
危険有害性情報: |
|
||||||||||||||
注意書き: |
|
説明
EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment.供給者とメーカー
weifang runzhong fine chemical co., ltd
HangZhou RunYan Pharma Technology Co.,LTD.
Hubei Yiling biotechnology Co Ltd
Hebei Yanxi Chemical Co., Ltd.
Anhui Ruihan Technology Co., Ltd
Shaanxi TNJONE Pharmaceutical Co., Ltd
ATK CHEMICAL COMPANY LIMITED
Jinan Jianfeng Chemical Co., Ltd
Shenzhen Nexconn Pharmatechs Ltd
Shaanxi Dideu Medichem Co. Ltd